APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Osteoporosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Postmenopausal Osteoporosis Drugs Market Analysis and Forecast 2026-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchPostmenopausal Osteoporosis Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Osteoporosis Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Postmenopausal Osteoporosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Osteoporosis Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Osteoporosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Postmenopausal Osteoporosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Postmenopausal Osteoporosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Postmenopausal Osteoporosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Postmenopausal Osteoporosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Postmenopausal Osteoporosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Postmenopausal Osteoporosis Drugs include Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, PhytoHealth, Radius Health and Tarsa Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Postmenopausal Osteoporosis Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Postmenopausal Osteoporosis Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Postmenopausal Osteoporosis Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Postmenopausal Osteoporosis Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Postmenopausal Osteoporosis Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Postmenopausal Osteoporosis Drugs sales, projected growth trends, production technology, application and end-user industry.

Postmenopausal Osteoporosis Drugs Segment by Company

Allergan

Amgen Astellas Biopharm

Deltanoid Pharmaceuticals

Noven

Novo Nordisk

Osteologix

PhytoHealth

Radius Health

Tarsa Therapeutics

Amgen

Pfizer

Eli Lilly

Merck

Novartis

Postmenopausal Osteoporosis Drugs Segment by Type

Antiresorptive Medications

Anabolic Medications

Postmenopausal Osteoporosis Drugs Segment by Application

Hospital

Pharmacy

Other

Postmenopausal Osteoporosis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Osteoporosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Postmenopausal Osteoporosis Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Postmenopausal Osteoporosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Postmenopausal Osteoporosis Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Postmenopausal Osteoporosis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antiresorptive Medications Major Manufacturers Table 3. Anabolic Medications Major Manufacturers Table 4. Global Postmenopausal Osteoporosis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Pharmacy Major Manufacturers Table 7. Other Major Manufacturers Table 8. Postmenopausal Osteoporosis Drugs Industry Trends Table 9. Postmenopausal Osteoporosis Drugs Industry Drivers Table 10. Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges Table 11. Postmenopausal Osteoporosis Drugs Industry Restraints Table 12. Global Postmenopausal Osteoporosis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Postmenopausal Osteoporosis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Postmenopausal Osteoporosis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2021-2026) Table 16. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2027-2032) Table 17. Global Postmenopausal Osteoporosis Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2026) & (K Units) Table 19. Global Postmenopausal Osteoporosis Drugs Sales by Region (2027-2032) & (K Units) Table 20. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2021-2026) Table 21. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2027-2032) Table 22. Global Postmenopausal Osteoporosis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Postmenopausal Osteoporosis Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global Postmenopausal Osteoporosis Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Postmenopausal Osteoporosis Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Postmenopausal Osteoporosis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Postmenopausal Osteoporosis Drugs Manufacturers, Product Type & Application Table 30. Global Postmenopausal Osteoporosis Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Postmenopausal Osteoporosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Postmenopausal Osteoporosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2026) Table 37. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2027-2032) Table 38. Global Postmenopausal Osteoporosis Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 40. Global Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 41. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2026) Table 42. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2027-2032) Table 43. Global Postmenopausal Osteoporosis Drugs Price by Type (2021-2026) & (US$/Unit) Table 44. Global Postmenopausal Osteoporosis Drugs Price by Type (2027-2032) & (US$/Unit) Table 45. Global Postmenopausal Osteoporosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2026) Table 49. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2027-2032) Table 50. Global Postmenopausal Osteoporosis Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 53. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2026) Table 54. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2027-2032) Table 55. Global Postmenopausal Osteoporosis Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global Postmenopausal Osteoporosis Drugs Price by Application (2027-2032) & (US$/Unit) Table 57. Allergan Company Information Table 58. Allergan Business Overview Table 59. Allergan Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Allergan Postmenopausal Osteoporosis Drugs Product Portfolio Table 61. Allergan Recent Development Table 62. Amgen Astellas Biopharm Company Information Table 63. Amgen Astellas Biopharm Business Overview Table 64. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio Table 66. Amgen Astellas Biopharm Recent Development Table 67. Deltanoid Pharmaceuticals Company Information Table 68. Deltanoid Pharmaceuticals Business Overview Table 69. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio Table 71. Deltanoid Pharmaceuticals Recent Development Table 72. Noven Company Information Table 73. Noven Business Overview Table 74. Noven Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Noven Postmenopausal Osteoporosis Drugs Product Portfolio Table 76. Noven Recent Development Table 77. Novo Nordisk Company Information Table 78. Novo Nordisk Business Overview Table 79. Novo Nordisk Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio Table 81. Novo Nordisk Recent Development Table 82. Osteologix Company Information Table 83. Osteologix Business Overview Table 84. Osteologix Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio Table 86. Osteologix Recent Development Table 87. PhytoHealth Company Information Table 88. PhytoHealth Business Overview Table 89. PhytoHealth Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio Table 91. PhytoHealth Recent Development Table 92. Radius Health Company Information Table 93. Radius Health Business Overview Table 94. Radius Health Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio Table 96. Radius Health Recent Development Table 97. Tarsa Therapeutics Company Information Table 98. Tarsa Therapeutics Business Overview Table 99. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio Table 101. Tarsa Therapeutics Recent Development Table 102. Amgen Company Information Table 103. Amgen Business Overview Table 104. Amgen Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Amgen Postmenopausal Osteoporosis Drugs Product Portfolio Table 106. Amgen Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio Table 111. Pfizer Recent Development Table 112. Eli Lilly Company Information Table 113. Eli Lilly Business Overview Table 114. Eli Lilly Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio Table 116. Eli Lilly Recent Development Table 117. Merck Company Information Table 118. Merck Business Overview Table 119. Merck Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Merck Postmenopausal Osteoporosis Drugs Product Portfolio Table 121. Merck Recent Development Table 122. Novartis Company Information Table 123. Novartis Business Overview Table 124. Novartis Postmenopausal Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Novartis Postmenopausal Osteoporosis Drugs Product Portfolio Table 126. Novartis Recent Development Table 127. North America Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 130. North America Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 131. North America Postmenopausal Osteoporosis Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 132. North America Postmenopausal Osteoporosis Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 133. North America Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 136. North America Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 137. North America Postmenopausal Osteoporosis Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 138. North America Postmenopausal Osteoporosis Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 139. North America Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. North America Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. North America Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 143. North America Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 144. North America Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 145. North America Postmenopausal Osteoporosis Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 146. North America Postmenopausal Osteoporosis Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 147. United States Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 148. Canada Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 149. Europe Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 152. Europe Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 153. Europe Postmenopausal Osteoporosis Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 154. Europe Postmenopausal Osteoporosis Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 155. Europe Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 158. Europe Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 159. Europe Postmenopausal Osteoporosis Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 160. Europe Postmenopausal Osteoporosis Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 161. Europe Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Europe Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Europe Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Europe Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 165. Europe Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 166. Europe Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 167. Europe Postmenopausal Osteoporosis Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 168. Europe Postmenopausal Osteoporosis Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 169. Germany Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 170. France Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 171. U.K. Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 172. Italy Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 173. Netherlands Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 174. Nordic Countries Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 175. China Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 176. China Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 177. China Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 178. China Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 179. China Postmenopausal Osteoporosis Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 180. China Postmenopausal Osteoporosis Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 181. China Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 182. China Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 183. China Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 184. China Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 185. China Postmenopausal Osteoporosis Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 186. China Postmenopausal Osteoporosis Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 187. Asia Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. Asia Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. Asia Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 190. Asia Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 191. Asia Postmenopausal Osteoporosis Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 192. Asia Postmenopausal Osteoporosis Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 193. Asia Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. Asia Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. Asia Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 196. Asia Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 197. Asia Postmenopausal Osteoporosis Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 198. Asia Postmenopausal Osteoporosis Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 199. Asia Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Asia Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Asia Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Asia Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 203. Asia Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 204. Asia Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 205. Asia Postmenopausal Osteoporosis Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 206. Asia Postmenopausal Osteoporosis Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 207. Japan Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 208. South Korea Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 209. India Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 210. Australia Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 211. China Taiwan Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 212. Southeast Asia Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 213. SAMEA Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 214. SAMEA Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 215. SAMEA Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 216. SAMEA Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 217. SAMEA Postmenopausal Osteoporosis Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 218. SAMEA Postmenopausal Osteoporosis Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 219. SAMEA Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 222. SAMEA Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 223. SAMEA Postmenopausal Osteoporosis Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 224. SAMEA Postmenopausal Osteoporosis Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 225. SAMEA Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. SAMEA Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. SAMEA Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. SAMEA Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 229. SAMEA Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 230. SAMEA Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 231. SAMEA Postmenopausal Osteoporosis Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 232. SAMEA Postmenopausal Osteoporosis Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 233. Brazil Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 234. Argentina Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 235. Chile Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 236. Colombia Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 237. Peru Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 238. Saudi Arabia Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 239. Israel Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 240. UAE Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 241. Turkey Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 242. Iran Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 243. Egypt Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Table 244. Key Raw Materials Table 245. Raw Materials Key Suppliers Table 246. Postmenopausal Osteoporosis Drugs Distributors List Table 247. Postmenopausal Osteoporosis Drugs Customers List Table 248. Research Programs/Design for This Report Table 249. Authors List of This Report Table 250. Secondary Sources Table 251. Primary Sources List of Figures Figure 1. Postmenopausal Osteoporosis Drugs Image Figure 2. Global Postmenopausal Osteoporosis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Osteoporosis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antiresorptive Medications Image Figure 5. Anabolic Medications Image Figure 6. Global Postmenopausal Osteoporosis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Postmenopausal Osteoporosis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Postmenopausal Osteoporosis Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global Postmenopausal Osteoporosis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global Postmenopausal Osteoporosis Drugs Sales (2021-2032) & (K Units) Figure 17. Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Postmenopausal Osteoporosis Drugs Sales YoY (2021-2032) & (K Units) Figure 20. Europe Postmenopausal Osteoporosis Drugs Sales YoY (2021-2032) & (K Units) Figure 21. China Postmenopausal Osteoporosis Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Postmenopausal Osteoporosis Drugs Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Global Postmenopausal Osteoporosis Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Postmenopausal Osteoporosis Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2032) Figure 30. Global Postmenopausal Osteoporosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2032) Figure 33. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2032) Figure 36. Global Postmenopausal Osteoporosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2032) Figure 39. North America Postmenopausal Osteoporosis Drugs Revenue Share by Type (2021-2032) Figure 40. North America Postmenopausal Osteoporosis Drugs Sales Share by Type (2021-2032) Figure 41. North America Postmenopausal Osteoporosis Drugs Revenue Share by Application (2021-2032) Figure 42. North America Postmenopausal Osteoporosis Drugs Sales Share by Application (2021-2032) Figure 43. North America Postmenopausal Osteoporosis Drugs Revenue Share by Country (2021-2032) Figure 44. North America Postmenopausal Osteoporosis Drugs Sales Share by Country (2021-2032) Figure 45. Europe Postmenopausal Osteoporosis Drugs Revenue Share by Type (2021-2032) Figure 46. Europe Postmenopausal Osteoporosis Drugs Sales Share by Type (2021-2032) Figure 47. Europe Postmenopausal Osteoporosis Drugs Revenue Share by Application (2021-2032) Figure 48. Europe Postmenopausal Osteoporosis Drugs Sales Share by Application (2021-2032) Figure 49. Europe Postmenopausal Osteoporosis Drugs Revenue Share by Country (2021-2032) Figure 50. Europe Postmenopausal Osteoporosis Drugs Sales Share by Country (2021-2032) Figure 51. China Postmenopausal Osteoporosis Drugs Revenue Share by Type (2021-2032) Figure 52. China Postmenopausal Osteoporosis Drugs Sales Share by Type (2021-2032) Figure 53. China Postmenopausal Osteoporosis Drugs Revenue Share by Application (2021-2032) Figure 54. China Postmenopausal Osteoporosis Drugs Sales Share by Application (2021-2032) Figure 55. Asia Postmenopausal Osteoporosis Drugs Revenue Share by Type (2021-2032) Figure 56. Asia Postmenopausal Osteoporosis Drugs Sales Share by Type (2021-2032) Figure 57. Asia Postmenopausal Osteoporosis Drugs Revenue Share by Application (2021-2032) Figure 58. Asia Postmenopausal Osteoporosis Drugs Sales Share by Application (2021-2032) Figure 59. Asia Postmenopausal Osteoporosis Drugs Revenue Share by Country (2021-2032) Figure 60. Asia Postmenopausal Osteoporosis Drugs Sales Share by Country (2021-2032) Figure 61. SAMEA Postmenopausal Osteoporosis Drugs Revenue Share by Type (2021-2032) Figure 62. SAMEA Postmenopausal Osteoporosis Drugs Sales Share by Type (2021-2032) Figure 63. SAMEA Postmenopausal Osteoporosis Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Postmenopausal Osteoporosis Drugs Sales Share by Application (2021-2032) Figure 65. SAMEA Postmenopausal Osteoporosis Drugs Revenue Share by Country (2021-2032) Figure 66. SAMEA Postmenopausal Osteoporosis Drugs Sales Share by Country (2021-2032) Figure 67. Postmenopausal Osteoporosis Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Postmenopausal Osteoporosis Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Antiresorptive Medications
  • Anabolic Medications
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Allergan
  • Amgen Astellas Biopharm
  • Deltanoid Pharmaceuticals
  • Noven
  • Novo Nordisk
  • Osteologix
  • PhytoHealth
  • Radius Health
  • Tarsa Therapeutics
  • Amgen
  • Pfizer
  • Eli Lilly
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Postmenopausal Osteoporosis Drugs Market by Type
  3. 1.2.1 Global Postmenopausal Osteoporosis Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antiresorptive Medications
  5. 1.2.3 Anabolic Medications
  6. 1.3 Postmenopausal Osteoporosis Drugs Market by Application
  7. 1.3.1 Global Postmenopausal Osteoporosis Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Postmenopausal Osteoporosis Drugs Market Dynamics
  1. 2.1 Postmenopausal Osteoporosis Drugs Industry Trends
  2. 2.2 Postmenopausal Osteoporosis Drugs Industry Drivers
  3. 2.3 Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Osteoporosis Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Postmenopausal Osteoporosis Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Postmenopausal Osteoporosis Drugs Revenue by Region
  3. 3.2.1 Global Postmenopausal Osteoporosis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Postmenopausal Osteoporosis Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Postmenopausal Osteoporosis Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Postmenopausal Osteoporosis Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Postmenopausal Osteoporosis Drugs Sales by Region
  9. 3.4.1 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Postmenopausal Osteoporosis Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Postmenopausal Osteoporosis Drugs Revenue by Manufacturers
  2. 4.1.1 Global Postmenopausal Osteoporosis Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Postmenopausal Osteoporosis Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Postmenopausal Osteoporosis Drugs Sales by Manufacturers
  6. 4.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Postmenopausal Osteoporosis Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Postmenopausal Osteoporosis Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Postmenopausal Osteoporosis Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Postmenopausal Osteoporosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Postmenopausal Osteoporosis Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Postmenopausal Osteoporosis Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Postmenopausal Osteoporosis Drugs Market CR5 and HHI
  16. 4.8.2 2025 Postmenopausal Osteoporosis Drugs Tier 1, Tier 2, and Tier 3
5 Postmenopausal Osteoporosis Drugs Market by Type
  1. 5.1 Global Postmenopausal Osteoporosis Drugs Revenue by Type
  2. 5.1.1 Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Postmenopausal Osteoporosis Drugs Sales by Type
  6. 5.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Postmenopausal Osteoporosis Drugs Price by Type
6 Postmenopausal Osteoporosis Drugs Market by Application
  1. 6.1 Global Postmenopausal Osteoporosis Drugs Revenue by Application
  2. 6.1.1 Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Postmenopausal Osteoporosis Drugs Sales by Application
  6. 6.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Postmenopausal Osteoporosis Drugs Price by Application
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Postmenopausal Osteoporosis Drugs Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Amgen Astellas Biopharm
  8. 7.2.1 Amgen Astellas Biopharm Company Information
  9. 7.2.2 Amgen Astellas Biopharm Business Overview
  10. 7.2.3 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio
  12. 7.2.5 Amgen Astellas Biopharm Recent Developments
  13. 7.3 Deltanoid Pharmaceuticals
  14. 7.3.1 Deltanoid Pharmaceuticals Company Information
  15. 7.3.2 Deltanoid Pharmaceuticals Business Overview
  16. 7.3.3 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio
  18. 7.3.5 Deltanoid Pharmaceuticals Recent Developments
  19. 7.4 Noven
  20. 7.4.1 Noven Company Information
  21. 7.4.2 Noven Business Overview
  22. 7.4.3 Noven Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Noven Postmenopausal Osteoporosis Drugs Product Portfolio
  24. 7.4.5 Noven Recent Developments
  25. 7.5 Novo Nordisk
  26. 7.5.1 Novo Nordisk Company Information
  27. 7.5.2 Novo Nordisk Business Overview
  28. 7.5.3 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio
  30. 7.5.5 Novo Nordisk Recent Developments
  31. 7.6 Osteologix
  32. 7.6.1 Osteologix Company Information
  33. 7.6.2 Osteologix Business Overview
  34. 7.6.3 Osteologix Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio
  36. 7.6.5 Osteologix Recent Developments
  37. 7.7 PhytoHealth
  38. 7.7.1 PhytoHealth Company Information
  39. 7.7.2 PhytoHealth Business Overview
  40. 7.7.3 PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio
  42. 7.7.5 PhytoHealth Recent Developments
  43. 7.8 Radius Health
  44. 7.8.1 Radius Health Company Information
  45. 7.8.2 Radius Health Business Overview
  46. 7.8.3 Radius Health Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio
  48. 7.8.5 Radius Health Recent Developments
  49. 7.9 Tarsa Therapeutics
  50. 7.9.1 Tarsa Therapeutics Company Information
  51. 7.9.2 Tarsa Therapeutics Business Overview
  52. 7.9.3 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio
  54. 7.9.5 Tarsa Therapeutics Recent Developments
  55. 7.10 Amgen
  56. 7.10.1 Amgen Company Information
  57. 7.10.2 Amgen Business Overview
  58. 7.10.3 Amgen Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Amgen Postmenopausal Osteoporosis Drugs Product Portfolio
  60. 7.10.5 Amgen Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Eli Lilly
  68. 7.12.1 Eli Lilly Company Information
  69. 7.12.2 Eli Lilly Business Overview
  70. 7.12.3 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio
  72. 7.12.5 Eli Lilly Recent Developments
  73. 7.13 Merck
  74. 7.13.1 Merck Company Information
  75. 7.13.2 Merck Business Overview
  76. 7.13.3 Merck Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Merck Postmenopausal Osteoporosis Drugs Product Portfolio
  78. 7.13.5 Merck Recent Developments
  79. 7.14 Novartis
  80. 7.14.1 Novartis Company Information
  81. 7.14.2 Novartis Business Overview
  82. 7.14.3 Novartis Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Novartis Postmenopausal Osteoporosis Drugs Product Portfolio
  84. 7.14.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Postmenopausal Osteoporosis Drugs Market Size by Type
  2. 8.1.1 North America Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Postmenopausal Osteoporosis Drugs Price by Type (2021-2032)
  5. 8.2 North America Postmenopausal Osteoporosis Drugs Market Size by Application
  6. 8.2.1 North America Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Postmenopausal Osteoporosis Drugs Price by Application (2021-2032)
  9. 8.3 North America Postmenopausal Osteoporosis Drugs Market Size by Country
  10. 8.3.1 North America Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Postmenopausal Osteoporosis Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Postmenopausal Osteoporosis Drugs Market Size by Type
  2. 9.1.1 Europe Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Postmenopausal Osteoporosis Drugs Price by Type (2021-2032)
  5. 9.2 Europe Postmenopausal Osteoporosis Drugs Market Size by Application
  6. 9.2.1 Europe Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Postmenopausal Osteoporosis Drugs Price by Application (2021-2032)
  9. 9.3 Europe Postmenopausal Osteoporosis Drugs Market Size by Country
  10. 9.3.1 Europe Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Postmenopausal Osteoporosis Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Postmenopausal Osteoporosis Drugs Market Size by Type
  2. 10.1.1 China Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Postmenopausal Osteoporosis Drugs Price by Type (2021-2032)
  5. 10.2 China Postmenopausal Osteoporosis Drugs Market Size by Application
  6. 10.2.1 China Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Postmenopausal Osteoporosis Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Postmenopausal Osteoporosis Drugs Market Size by Type
  2. 11.1.1 Asia Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Postmenopausal Osteoporosis Drugs Price by Type (2021-2032)
  5. 11.2 Asia Postmenopausal Osteoporosis Drugs Market Size by Application
  6. 11.2.1 Asia Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Postmenopausal Osteoporosis Drugs Price by Application (2021-2032)
  9. 11.3 Asia Postmenopausal Osteoporosis Drugs Market Size by Country
  10. 11.3.1 Asia Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Postmenopausal Osteoporosis Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Postmenopausal Osteoporosis Drugs Market Size by Type
  2. 12.1.1 SAMEA Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Postmenopausal Osteoporosis Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Postmenopausal Osteoporosis Drugs Market Size by Application
  6. 12.2.1 SAMEA Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Postmenopausal Osteoporosis Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Postmenopausal Osteoporosis Drugs Market Size by Country
  10. 12.3.1 SAMEA Postmenopausal Osteoporosis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Postmenopausal Osteoporosis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Postmenopausal Osteoporosis Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Postmenopausal Osteoporosis Drugs Value Chain Analysis
  2. 13.1.1 Postmenopausal Osteoporosis Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Postmenopausal Osteoporosis Drugs Production Mode & Process
  6. 13.2 Postmenopausal Osteoporosis Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Postmenopausal Osteoporosis Drugs Distributors
  9. 13.2.3 Postmenopausal Osteoporosis Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst